Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Labetalol differs from propranolol in that:
A. It has additional α1 blocking property
B. It is a selective β1 blocker
C. It does not undergo first pass metabolism
D. All of the above
by

1 Answer

Answer :

A. It has additional α1 blocking property
by

Related questions

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Description : Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Last Answer : A. More potent β adrenergic blocking than α blocking activity

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Description : The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Last Answer : A. It is a weak Na+ channel blocker

Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α-reductase inhibitor used to reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Description : Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α- ... reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Last Answer : A. It is a PGF2α derivative used in glaucoma

Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α-reductase inhibitor used to reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Description : Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α- ... reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Last Answer : A. It is a PGF2α derivative used in glaucoma

The preferred class of drugs for long term treatment of severe anxiety disorder with intermittent panic attacks is: A. Phenothiazine (chlorpromazine like) B. Azapirone (buspirone like) C. β-blocker (propranolol like) D. Selective serotonin reuptake inhibitor (sertraline like)

Description : The preferred class of drugs for long term treatment of severe anxiety disorder with intermittent panic attacks is: A. Phenothiazine (chlorpromazine like) B. Azapirone (buspirone like) C. β-blocker (propranolol like) D. Selective serotonin reuptake inhibitor (sertraline like)

Last Answer : DD. Selective serotonin reuptake inhibitor (sertraline like)

The following is true of simvastatin except: A. It is more potent than lovastatin B. At the highest recommended dose, it causes greater LDL-cholesterol lowering than lovastatin C. It does not undergo first pass metabolism in liver D. It can raise HDL-cholesterol level when the same is low at base line

Description : The following is true of simvastatin except: A. It is more potent than lovastatin B. At the highest recommended dose, it causes greater LDL-cholesterol lowering than lovastatin C. It does not undergo ... metabolism in liver D. It can raise HDL-cholesterol level when the same is low at base line

Last Answer : C. It does not undergo first pass metabolism in liver

Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Description : Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Last Answer : C. Withdrawal is less likely to exacerbate angina pectoris

Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Pancuronium differs from tubocurarine in that: A. It is a depolarizing blocker B. Its action is not reversed by neostigmine C. It can cause rise in BP on rapid I.V. injection D. It causes marked histamine release

Description : Pancuronium differs from tubocurarine in that: A. It is a depolarizing blocker B. Its action is not reversed by neostigmine C. It can cause rise in BP on rapid I.V. injection D. It causes marked histamine release

Last Answer : C. It can cause rise in BP on rapid I.V. injection

The β3 adrenoceptor differs from the other subtypes of β receptor in that it: A. Is not blocked by the conventional doses of propranolol B. Is located primarily in the heart C. Regulates blood sugar level D. Is not coupled to G proteins

Description : The β3 adrenoceptor differs from the other subtypes of β receptor in that it: A. Is not blocked by the conventional doses of propranolol B. Is located primarily in the heart C. Regulates blood sugar level D. Is not coupled to G proteins

Last Answer : A. Is not blocked by the conventional doses of propranolol

The β 3 adrenoceptor differs from the other subtypes of β receptor in that it: A. Is not blocked by the conventional doses of propranolol B. Is located primarily in the heart C. Regulates blood sugar level D. Is not coupled to G proteins

Description : The β 3 adrenoceptor differs from the other subtypes of β receptor in that it: A. Is not blocked by the conventional doses of propranolol B. Is located primarily in the heart C. Regulates blood sugar level D. Is not coupled to G proteins

Last Answer : A. Is not blocked by the conventional doses of propranolol

Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Description : Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Last Answer : Answer : A

Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Description : Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Last Answer : Answer : D

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Last Answer : D. Both ‘B’ and ‘C’ are correct

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

ndapamide differs from other diuretics in that: A. It has selective antihypertensive action at doses which cause little diuresis B. It is a more efficacious antihypertensive C. Its antihypertensive action develops more rapidly D. All of the above

Description : ndapamide differs from other diuretics in that: A. It has selective antihypertensive action at doses which cause little diuresis B. It is a more efficacious antihypertensive C. Its antihypertensive action develops more rapidly D. All of the above

Last Answer : A. It has selective antihypertensive action at doses which cause little diuresis

Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Description : Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Last Answer : D. All of the above

The following is a tetracyclic antidepressant that has additional dopamine blocking and neuroleptic properties, as well as greater propensity to cause seizures in overdose: A. Amoxapine B. Doxepin C. Dothiepin D. Trazodone

Description : The following is a tetracyclic antidepressant that has additional dopamine blocking and neuroleptic properties, as well as greater propensity to cause seizures in overdose: A. Amoxapine B. Doxepin C. Dothiepin D. Trazodone

Last Answer : A. Amoxapine

The following antipsychotic drug has weak dopamine D2 but additional 5-HT2 blocking activity and benefits both positive and negative symptoms of schizophrenia: A. Loxapine B. Clozapine C. Pimozide D. Penfluridol

Description : The following antipsychotic drug has weak dopamine D2 but additional 5-HT2 blocking activity and benefits both positive and negative symptoms of schizophrenia: A. Loxapine B. Clozapine C. Pimozide D. Penfluridol

Last Answer : B. Clozapin

Compared to other antipsychotic drugs, the distinctive feature of penfluridol is: A. Very long duration of action B. Weak dopamine D2 blocking activity C. Lack of extrapyramidal side effects D. Additional 5-HT2 receptor blocking activity

Description : Compared to other antipsychotic drugs, the distinctive feature of penfluridol is: A. Very long duration of action B. Weak dopamine D2 blocking activity C. Lack of extrapyramidal side effects D. Additional 5-HT2 receptor blocking activity

Last Answer : A. Very long duration of action

The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are incompletely absorbed after oral administration C. They are devoid of CNS and ocular effects D. Dose to dose they are more potent than atropine

Description : The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are ... of CNS and ocular effects D. Dose to dose they are more potent than atropine

Last Answer : C. They are devoid of CNS and ocular effects

Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Description : Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Last Answer : D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Description : Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Last Answer : D. All of the above are correct

Select the correct statement about salmeterol. (a) It is a long acting selective ß2 agonist bronchodilator (b) It is a bronchodilator with anti-inflammatory property (c) It is a ß blocker that can be safely given to asthmatics (d) It is an antihistaminic with mast cells stabilizing property

Description : Select the correct statement about salmeterol. (a) It is a long acting selective ß2 agonist bronchodilator (b) It is a bronchodilator with anti-inflammatory property (c) It is a ß blocker that can be safely given to asthmatics (d) It is an antihistaminic with mast cells stabilizing property

Last Answer : Ans: A

Select the correct statement about salmeterol: A. It is a long acting selective β2 agonist bronchodilator B. It is a bronchodilator with anti-inflammatory property C. It is a β blocker that can be safely given to asthmatics D. It is an antihistaminic with mast cell stabilizing property

Description : Select the correct statement about salmeterol: A. It is a long acting selective β2 agonist bronchodilator B. It is a bronchodilator with anti-inflammatory property C. It is a β blocker that can be safely given to asthmatics D. It is an antihistaminic with mast cell stabilizing property

Last Answer : A. It is a long acting selective β2 agonist bronchodilator

Select the drug that undergoes extensive first-pass metabolism in the liver: A. Phenobarbitone B. Propranolol C. Phenylbutazone D. Theophylline

Description : Select the drug that undergoes extensive first-pass metabolism in the liver: A. Phenobarbitone B. Propranolol C. Phenylbutazone D. Theophylline

Last Answer : B. Propranolol

Select the drug that undergoes extensive first-pass metabolism in the liver: A. Phenobarbitone B. Propranolol C. Phenylbutazone D. Theophylline

Description : Select the drug that undergoes extensive first-pass metabolism in the liver: A. Phenobarbitone B. Propranolol C. Phenylbutazone D. Theophylline

Last Answer : B. Propranolol

Choose the correct statement about trimetazidine: A. It is a novel calcium channel blocker B. It improves tissue perfusion by modifying rheological property of blood C. It is an antianginal drug which acts by nonhaemodynamic mechanisms D. Both 'A' and 'B' are correct

Description : Choose the correct statement about trimetazidine: A. It is a novel calcium channel blocker B. It improves tissue perfusion by modifying rheological property of blood C. It is an antianginal drug which acts by nonhaemodynamic mechanisms D. Both 'A' and 'B' are correct

Last Answer : C. It is an antianginal drug which acts by nonhaemodynamic mechanisms

Drugs which undergo high degree of first-pass metabolism in liver: A. Have low oral bioavailability B. Are excreted primarily in bile C. Are contraindicated in liver disease D. Exhibit zero order kinetics of elimination

Description : Drugs which undergo high degree of first-pass metabolism in liver: A. Have low oral bioavailability B. Are excreted primarily in bile C. Are contraindicated in liver disease D. Exhibit zero order kinetics of elimination

Last Answer : A. Have low oral bioavailability

Drugs which undergo high degree of first-pass metabolism in liver: A. Have low oral bioavailability B. Are excreted primarily in bile C. Are contraindicated in liver disease D. Exhibit zero order kinetics of elimination

Description : Drugs which undergo high degree of first-pass metabolism in liver: A. Have low oral bioavailability B. Are excreted primarily in bile C. Are contraindicated in liver disease D. Exhibit zero order kinetics of elimination

Last Answer : A. Have low oral bioavailability

Fexofenadine differs from terfenadine in that: A. It undergoes high first pass metabolism in liver B. It is a prodrug C. It does not block cardiac delayed rectifier K+ channels D. It has high affinity for central H1 receptors

Description : Fexofenadine differs from terfenadine in that: A. It undergoes high first pass metabolism in liver B. It is a prodrug C. It does not block cardiac delayed rectifier K+ channels D. It has high affinity for central H1 receptors

Last Answer : C. It does not block cardiac delayed rectifier K+ channels

Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Description : Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Last Answer : D. All of the above

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Venlafaxine differs from standard tricyclic antidepressants in that it: A. Does not inhibit 5-HT reuptake B. Does not inhibit noradrenaline reuptake C. Does not have anticholinergic or antiadrenergic property D. Has lower antidepressant efficacy

Description : Venlafaxine differs from standard tricyclic antidepressants in that it: A. Does not inhibit 5-HT reuptake B. Does not inhibit noradrenaline reuptake C. Does not have anticholinergic or antiadrenergic property D. Has lower antidepressant efficacy

Last Answer : C. Does not have anticholinergic or antiadrenergic property

Transferrin is a type of (A) Albumin (B) α-globulin (C) β1 globulin (D) γ-globulin MINERAL METABOLISM 203

Description : Transferrin is a type of (A) Albumin (B) α-globulin (C) β1 globulin (D) γ-globulin MINERAL METABOLISM 203

Last Answer : Answer : B

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the β blocker which does not afford prophylaxis in migraine: A. Propranolol B. Timolol C. Atenolol D. Pindolol

Description : Select the β blocker which does not afford prophylaxis in migraine: A. Propranolol B. Timolol C. Atenolol D. Pindolol

Last Answer : D. Pindolol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

he dominant pharmacokinetic feature of penicillin G is: A. It is equally distributed extra- and intracellularly B. It is rapidly secreted by proximal renal tubules C. It has low oral bioavailability due to high first pass metabolism in liver D. It does not cross blood–CSF barrier even when meninges are inflamed

Description : he dominant pharmacokinetic feature of penicillin G is: A. It is equally distributed extra- and intracellularly B. It is rapidly secreted by proximal renal tubules C. It has low oral bioavailability ... pass metabolism in liver D. It does not cross blood-CSF barrier even when meninges are inflamed

Last Answer : B. It is rapidly secreted by proximal renal tubules